286 related articles for article (PubMed ID: 27755242)
41. Advanced Echocardiographic Techniques in Cardio-Oncology: the Role for Early Detection of Cardiotoxicity.
Cobarro Gálvez L; Arbas Redondo E; Contreras Lorenzo C; López Fernández T
Curr Cardiol Rep; 2022 Sep; 24(9):1109-1116. PubMed ID: 35881319
[TBL] [Abstract][Full Text] [Related]
42. Role of biomarkers in monitoring antiblastic cardiotoxicity.
Novo G; Cadeddu C; Sucato V; Pagliaro P; Romano S; Tocchetti CG; Zito C; Longobardo L; Nodari S; Penco M
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S27-34. PubMed ID: 27183522
[TBL] [Abstract][Full Text] [Related]
43. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity due to chemotherapy: role of cardiac imaging.
Poulin F; Thavendiranathan P
Curr Cardiol Rep; 2015 Mar; 17(3):564. PubMed ID: 25648628
[TBL] [Abstract][Full Text] [Related]
45. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
[TBL] [Abstract][Full Text] [Related]
46. Three-dimensional echocardiography and cardiac magnetic resonance imaging in the screening of long-term survivors of childhood cancer after cardiotoxic therapy.
Ylänen K; Eerola A; Vettenranta K; Poutanen T
Am J Cardiol; 2014 Jun; 113(11):1886-92. PubMed ID: 24837269
[TBL] [Abstract][Full Text] [Related]
47. The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges.
Park CJ; Branch ME; Vasu S; Meléndez GC
J Cardiovasc Transl Res; 2020 Jun; 13(3):367-376. PubMed ID: 32248349
[TBL] [Abstract][Full Text] [Related]
48. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity.
de Geus-Oei LF; Mavinkurve-Groothuis AM; Bellersen L; Gotthardt M; Oyen WJ; Kapusta L; van Laarhoven HW
J Nucl Med Technol; 2013 Sep; 41(3):170-81. PubMed ID: 23929800
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics-Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging.
Toro-Salazar OH; Ferranti J; Lorenzoni R; Walling S; Mazur W; Raman SV; Davey BT; Gillan E; O'Loughlin M; Klas B; Hor KN
J Am Soc Echocardiogr; 2016 Feb; 29(2):119-31. PubMed ID: 26678319
[TBL] [Abstract][Full Text] [Related]
50. Echocardiography Imaging of Cardiotoxicity.
Kang Y; Scherrer-Crosbie M
Cardiol Clin; 2019 Nov; 37(4):419-427. PubMed ID: 31587783
[TBL] [Abstract][Full Text] [Related]
51. State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach.
Jokar N; Amini A; Ravanbod M; Barekat M; Shooli H; Gholamrezanezhad A; Assadi M
Nucl Med Rev Cent East Eur; 2021; 24(2):82-92. PubMed ID: 34382672
[TBL] [Abstract][Full Text] [Related]
52. Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient.
Plana JC; Thavendiranathan P; Bucciarelli-Ducci C; Lancellotti P
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1173-1186. PubMed ID: 30092972
[TBL] [Abstract][Full Text] [Related]
53. [Training and accreditation in cardiovascular magnetic resonance imaging: a position paper of the Working Group on Magnetic Resonance Imaging of the Italian Society of Cardiology and of the Working Group on Cardiovascular Imaging of the Italian Association of Hospital Cardiologists].
Roghi A; Dellegrottaglie S; Perna GP; ;
G Ital Cardiol (Rome); 2012 Feb; 13(2):138-41. PubMed ID: 22322556
[TBL] [Abstract][Full Text] [Related]
54. Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction.
Ong DS; Scherrer-Crosbie M; Coelho-Filho O; Francis SA; Neilan TG
Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):487-97. PubMed ID: 24650314
[TBL] [Abstract][Full Text] [Related]
55. Role of biomarkers in chemotherapy-induced cardiotoxicity.
Cardinale D; Sandri MT
Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
[TBL] [Abstract][Full Text] [Related]
56. Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to "Omics" Technologies.
Madonna R
Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):576-582. PubMed ID: 28246019
[TBL] [Abstract][Full Text] [Related]
57. The Role of Multimodality Cardiac Imaging in Patients Undergoing Cancer Treatment.
Wengrofsky P; Feldman S
Curr Cardiol Rep; 2023 Jan; 25(1):1-8. PubMed ID: 36527535
[TBL] [Abstract][Full Text] [Related]
58. Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity.
Cannizzaro MT; Inserra MC; Passaniti G; Celona A; D'Angelo T; Romeo P; Basile A
Heliyon; 2023 Apr; 9(4):e15226. PubMed ID: 37095987
[TBL] [Abstract][Full Text] [Related]
59. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
60. Emerging role of PET/MR in the diagnosis and characterization of cardiotoxicity?
Schindler TH; Sivapackiam J; Sharma V
Int J Cardiol; 2023 Aug; 385():82-84. PubMed ID: 37201611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
